Cilostazol milrinone

The PDE3 inhibitor, cilostazol, has been used as an antithrombotic agent and is currently being used in patients being treated for intermittent claudication. Cilostazol is also used for the prevention of restenosis after treatments such as angioplasty. Another PDE3 selective inhibitor, milrinone, has been used in the treatment of congestive heart failure. Milrinone also has been shown to increase the conductance of the CFTR transporter in vitro. 

PDE3 cGMP-inhibited PDE cAMP cGMP cGMP, milrinone, amrinone, anagrelide, cilostazol, lixazinone, NSP-513... 

CYP450 system Anagrelide enhanced the inhibition of platelet aggregation by aspirin and is an inhibitor of cyclic AMP PDE III (may exaggerate the properties of milrinone, enoximone, amrinone, olprinone, and cilostazol). 

Cilostazol is indicated for symptomatic relief of intermittent claudication (46,47). With recent attention focusing on new antiplatelet modalities in percutaneous coronary intervention, renewed interest in cilostazol has emerged. Although cilostazol has not been associated with the same increase in cardiac mortality noted with other PDE3 inhibitors used in patients with heart failure (such as milrinone), it is not recommended for use in patients with coexistent heart failure. 

---